Close Menu

NEW YORK – Oncocyte said on Thursday that it is collaborating with the Fondazione Michelangelo in Milan, Italy to evaluate the company's DetermaIO test as a therapy response predictor in the NeoTRIPaPDL1 trial.

DetermaIO is a tissue-based gene expression assay, designed to evaluate signals associated with the tumor immune microenvironment. The test stratifies patients according to their likelihood of responding to immunotherapy.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New Scientist reports that a new genetic analysis suggests some saber-toothed cats may have lived in packs and been fast runners.

A small study has found that a rapid test for SARS-CoV-2 works about as well as a PCR test, according to the New York Times.

PLOS is piloting a new model under which research institutions pay a flat fee for its researchers to publish in its journals, Science reports.

In Science this week: honey bees recognize colony mates by their gut microbiomes, and more.